ChartMill · Aug 11, 2026
Vericel Corp (NASDAQ:VCEL): Growth at a Reasonable Price
Vericel (VCEL) fits the affordable growth screen with strong EPS/revenue growth, reasonable valuation vs peers, and solid profitability.
VC
NASDAQ · VCEL
Vericel Corporation
Healthcare · Biotechnology
$44.73
Down-$0.19 (-0.42%)
Updated Aug 14, 2026, 12:17 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.89B
- P/E ratio
- 144.38
- Dividend yield
- 0.00%
- 52-week range
- $28.95 – $49.32
- Volume
- 290.76K
- Avg. volume
- 728.95K
Price performance
VCEL price history
1M range · 0 trading sessions · Daily adjusted prices
VCEL does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest VCEL news
The latest Smart Investors Daily articles mentioning VCEL.
Stock researchCompany · Overview
VCEL research
Overview
Company profile and research snapshot.
Company profile
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $41.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 31, 2026 | TD Cowen | Buy | — |
| Jul 31, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 31, 2026 | Truist Securities | Buy | — |
| Jul 28, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 16, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 3, 2026
Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison
IPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a […]
Benzinga · Jul 31, 2026
TD Cowen Maintains Buy on Vericel, Raises Price Target to $58
TD Cowen analyst Joshua Jennings maintains Vericel (NASDAQ:VCEL) with a Buy and raises the price target from $55 to $58.
Benzinga · Jul 31, 2026
Truist Securities Reiterates Buy on Vericel, Raises Price Target to $58
Truist Securities analyst Richard Newitter reiterates Vericel (NASDAQ:VCEL) with a Buy and raises the price target from $54 to $58.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
